1. Home
  2. KALV vs NX Comparison

KALV vs NX Comparison

Compare KALV & NX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo KalVista Pharmaceuticals Inc.

KALV

KalVista Pharmaceuticals Inc.

HOLD

Current Price

$26.71

Market Cap

1.0B

Sector

Health Care

ML Signal

HOLD

Logo Quanex Building Products Corporation

NX

Quanex Building Products Corporation

HOLD

Current Price

$20.08

Market Cap

852.1M

Sector

Industrials

ML Signal

HOLD

Company Overview

Basic Information
Metric
KALV
NX
Founded
N/A
1927
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Metal Fabrications
Sector
Health Care
Industrials
Exchange
Nasdaq
Nasdaq
Market Cap
1.0B
852.1M
IPO Year
2014
2008

Fundamental Metrics

Financial Performance
Metric
KALV
NX
Price
$26.71
$20.08
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
5
1
Target Price
$32.60
$28.00
AVG Volume (30 Days)
4.4M
261.0K
Earning Date
07-09-2026
06-04-2026
Dividend Yield
N/A
1.64%
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$50,000,000.00
$1,837,641,000.00
Revenue This Year
$185.42
$4.26
Revenue Next Year
$59.23
$1.77
P/E Ratio
N/A
N/A
Revenue Growth
495.66
43.81
52 Week Low
$9.83
$11.04
52 Week High
$26.85
$22.90

Technical Indicators

Market Signals
Indicator
KALV
NX
Relative Strength Index (RSI) 75.12 54.07
Support Level $14.66 $18.50
Resistance Level N/A $22.64
Average True Range (ATR) 0.44 0.71
MACD 0.35 -0.05
Stochastic Oscillator 98.23 64.20

Price Performance

Historical Comparison
KALV
NX

About KALV KalVista Pharmaceuticals Inc.

KalVista Pharmaceuticals Inc is a pharmaceutical company developing and delivering oral therapies for individuals affected by rare diseases with unmet needs. The company applies its knowledge in the kallikrein-kinin system (KKS) and oral drug discovery to develop small-molecule protease inhibitor medicines to address the needs of patients with diseases driven by plasma kallikrein and Factor XIIa. Its FDA-approved product EKTERLY (sebetralstat) is a novel, orally delivered, small-molecule plasma kallikrein inhibitor for the treatment of acute attacks of hereditary angioedema (HAE) in adult and pediatric patients aged twelve years and older.

About NX Quanex Building Products Corporation

Quanex Building Products Corp is a manufacturer of components sold to original equipment manufacturers in the building products industry. It manufactures engineered products like window and door components that include flexible insulating glass spacers, extruded vinyl profiles, window and door screens, solar panel sealants and precision-formed metal and wood products among others. Its four operating segments are North American Fenestration being the key revenue driver, European Fenestration, North American Cabinet Components, and Tyman. Geographically, it derives a majority of revenue from the United States.

Share on Social Networks: